A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase III
Latest Information Update: 11 Feb 2019
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms COLUMBA
- Sponsors Janssen Research & Development
- 04 Dec 2018 Results assessing activation of adaptive and innate immunity in daratumumab and IMiDs treated MM patients from MMY3012 and MM014 trial, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 25 Apr 2018 According to a Genmab media release, data from the study will be presented at the 2018 ASCO Annual Meeting.